The BrIMA clinical trial, which tracked 148 patients across Belgium, Germany, and Italy, found that integrating molecular imaging directly into the operating room allows surgeons to make immediate, informed decisions. For patients with invasive ductal carcinoma, success rates climbed from 83.3% to 95.2% when utilizing the system. Across all breast cancer subtypes, the technology boosted success rates from 76.4% to 91.9%.
New PET-CT Imaging Improves Breast Surgery Success Rates
Surgeons face a persistent challenge in breast-conserving procedures: positive margins that often trigger the need for secondary operations. A new multicenter study published in JAMA Surgery suggests that using the AURA 10 specimen PET-CT system during surgery can identify these margins in real-time, significantly reducing the likelihood of repeat procedures.
Unlike traditional methods that rely on limited two-dimensional snapshots or partial specimen analysis, the AURA 10 provides high-resolution, three-dimensional visualization. The device delivers results in roughly ten minutes, fitting into the existing surgical workflow without requiring tissue transport. Vincent Keereman, CEO of XEOS, noted that the primary advantage lies in providing actionable data while the patient is still under anesthesia. Dr. Menekse Göker, the study's primary author, emphasized that the technology effectively bridges the gap between initial excision and postoperative pathology, potentially sparing patients the physical and emotional burden of follow-up surgeries.
Comments (0)
No comments yet. Be the first!